NxStage Medical, Inc. (NASDAQ:NXTM) SVP Winifred L. Swan sold 3,500 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $24.48, for a total transaction of $85,680.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
NxStage Medical, Inc. (NASDAQ NXTM) traded down $0.25 during trading hours on Friday, reaching $24.13. 646,500 shares of the company’s stock were exchanged, compared to its average volume of 513,274. The firm has a market capitalization of $1,616.90, a PE ratio of -344.71 and a beta of -0.08. NxStage Medical, Inc. has a 1-year low of $20.45 and a 1-year high of $30.80.
Several equities research analysts have recently weighed in on NXTM shares. Zacks Investment Research upgraded shares of NxStage Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Northland Securities restated a “hold” rating and issued a $30.00 price target on shares of NxStage Medical in a report on Wednesday, November 8th. ValuEngine cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Finally, BidaskClub upgraded shares of NxStage Medical from a “strong sell” rating to a “sell” rating in a report on Monday, February 5th. Three analysts have rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $30.25.
COPYRIGHT VIOLATION WARNING: “NxStage Medical, Inc. (NXTM) SVP Winifred L. Swan Sells 3,500 Shares” was published by Week Herald and is owned by of Week Herald. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://weekherald.com/2018/02/23/nxstage-medical-inc-nxtm-svp-winifred-l-swan-sells-3500-shares.html.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.